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SUMMARY
A method for simultaneously quantifying dopamine, 5-hydroxytryptamine (5-HT) and four
metabolically related compounds has been developed, permitting more efficient neurochemical
examination of these often interrelated biogenic amine systems. The method uses high-
performance liquid chromatographic separation of these compounds on a C18 reversed-phase
column with a buffered mobile phase containing methanol as an organic modifier and
heptanesulfonate as an ion-pair reagent. Using 5-hydroxy-N-methyltryptamine as an internal
standard and electrochemical detection, chromatography time is less than 12 min. Sample
preparation simply involves the addition of internal standard, homogenization in the mobile phase,
centrifugation and injection of the supernatant into the chromatograph. The method is sensitive to
a tissue content of these compounds of less than 1 ng. The utility of this method for
neuropharmacological—neurochemical studies is illustrated with studies using inhibitors of
monoamine oxidase (pargyline) and aromatic amino acid decarboxylase (RO 4-4602).
INTRODUCTION
The involvement of dopamine- and 5-hydroxytryptamine (5-HT)-containing neuronal
systems in the function of the central nervous system (CNS) is well documented. Evidence
obtained from diverse lines of investigation support the existence of functional interactions
between neuronal elements containing these two putative neurotransmitters [1—3]. It is
therefore of interest to be able to assess simultaneously changes in the functional state of
both of these systems.
Biochemical determinations of the rate of neurotransmitter turnover have proven to be
useful estimates of the activity of neuronal systems. For dopamine systems, the available
nonradiometric techniques include: (1) measurement of the rate of accumulation of 3,4-
dihydroxyphenylalanine (DOPA) following decarboxylase inhibition [4]; (2) the rate of
decrease in dopamine concentration following synthesis inhibition with α-methyltyrosine
[5]; and (3) the concentration of 3,4-dihydroxyphenylacetic acid (DOPAC) or 3-methoxy-4-
hydroxyphenylacetic acid (HVA) at a steady state [6,7] or following inhibition of their
formation or transport [8,9]. Similarly, the biochemical estimation of changes in 5-HT
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turnover have been employed as an index of changes in the functional state of 5-HT neurons
in the CNS. These techniques include: (1) measurement of the rate of accumulation of 5-
hydroxytryptophan (5-HTP) following decarboxylase inhibition [4,10]; (2) the rate of
accumulation of 5-HT following inhibition of its metabolism [11,12]; and (3) the
concentration of 5-hydroxyindoleacetic acid (5-HIAA) at a steady state [13] or following
inhibition of its formation [11] or transport [14].
The heterogeneous distribution, function, and regulation of dopamine and 5-HT systems in
the CNS necessitates the use of analytical techniques with sensitivity requisite for
determinations in small brain regions. A variety of separation and detection methods have
been used to quantify the precursors and metabolites of dopamine and 5-HT. Of these
techniques, the greatest degrees of flexibility, sensitivity and specificity have been obtained
using either gas chromatography with electron-capture or mass fragmentographic detection
[15—21], or high-performance liquid chromatography (HPLC) using fluorometric or
electrochemical detection [22—37]. However, each of these techniques has potential
shortcomings in at least one of the following criteria: speed; sensitivity; specificity;
flexibility; sample purification and/or concentration; use of internal standards to monitor
recovery during sample preparation; or complexity of instrumentation.
The present study reports a method for the simultaneous determination of dopamine,
DOPAC, HVA, 5-HTP, 5-HT and 5-HIAA in samples from small brain regions by means of
ion-pair, reversed-phase HPLC with electrochemical detection. N-Methyl-5-
hydroxytryptamine is used as an internal standard. This assay offers considerable advantages
in terms of ease of sample preparation, internal standardization and versatility, and offers
sufficient sensitivity to perform accurate determinations in tissue samples as small as 1 mg.
EXPERIMENTAL
Reagents and drugs
Chemicals were obtained from the following sources: dopamine hydrochloride, 3,4-
dihydroxyphenylacetic acid, 3-methoxy-4-hydroxyphenylacetic acid, 5-hydroxytryptamine
creatinine sulfate and 5-hydroxyindoleacetic acid were obtained from Sigma (St. Louis, MO,
U.S.A.); 5-hydroxytryptophan from Calbiochem (Los Angeles, CA, U.S.A.); 5-hydroxy-N-
methyltryptamine oxalate (N-methyl-5-HT) from Aldrich (Milwaukee, WI, U.S.A.); sodium
1-heptane-sulfonate from Eastman-Kodak (Rochester, NY, U.S.A.); pargyline hydrochloride
from Abbott Laboratories (North Chicago, IL, U.S.A.); and RO 4-4602 [N-(DL-seryl-N)-
(2,3,4-trihydroxybenzyl)hydrazine] from Hoffmann-LaRoche (Nutley, NJ, U.S.A.). Reagent
grade methanol (Fisher Scientific, Fairlawn, NJ, U.S.A.) was used as supplied.
Apparatus
A Laboratory Data Control (Riviera Beach, FL, U.S.A.) ConstaMetric IIG solvent delivery
pump was used in conjunction with a TL-5 glassy carbon electrode and an LC-4 controller,
both from Bioanalytical Systems (West Lafayette, IN, U.S.A.). The detector potential was
maintained at 0.75 V vs. a Ag/AgCl reference electrode. A six port rotary valve (Model
7125, Rheodyne, Berkeley, CA, U.S.A.) with a 500-μ1 sample loop was used for sample
injection. Chromatographic separations were performed using a 25 cm × 4.6 mm I.D.
stainless-steel column packed with octadecylsilane (C18) on microparticulate (5 μm) silica
gel (Spherisorb ODS, Applied Science Labs., State College, PA, U.S.A.). A precolumn filter
with a 2-μm frit (Rheodyne) effectively minimized the accumulation of particulate matter on
the analytical column.
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The mobile phase was a mixture of 0.1 M citrate, 0.075 M Na2HPO4, 0.75 mM sodium
heptanesulfonate and 14% methanol (v/v). After adjusting to pH* 3.9, the mobile phase was
filtered through a 0.45-μm filter (Gelman Sciences, Ann Arbor, MI, U.S.A.) and degassed
under vacuum with ultrasonic agitation. All separations were performed isocratically at a
flow-rate of 1.5 ml/min.
Standards
Stock solutions of the reference and internal standards were prepared in the mobile phase at
a concentration of 1 μg/μl (calculated as the free compound) and stored at 4°C. Working
solutions (1 ng/μl) were prepared at weekly intervals by a 1:1000 dilution of the stock
solutions using the mobile phase as the diluent.
Calculations
Standard curves were prepared by analyzing a series of standard solutions containing a fixed
amount (10 or 25 ng) of the internal standard and varying amounts of dopamine, DOPAC,
HVA, 5-HTP, 5-HT and 5-HIAA. These standards, in 400-μl aliquots of the mobile phase,
were subjected to the identical preparative procedures used for tissue samples. The ratio of
the detector response for each compound versus that of the internal standard was determined
for each sample and standard. The concentrations of dopamine, DOPAC, HVA, 5-HTP, 5-
HT and 5-HIAA in tissue samples were calculated from the ratio of their detector response
relative to that of the internal standard using the slope and intercept of the standard curve.
Sample preparation
Male Sprague-Dawley rats (200—275 g; Charles River Laboratories, Wimington, MA,
U.S.A.) were sacrificed by decapitation and the brain rapidly removed. The olfactory
tubercles, nucleus accumbens and striata were dissected and placed in 500-μl nalgene tubes
(No. 1801, Denville Scientific, Denville, NJ, U.S.A.) containing 400 μl of mobile phase and
the internal standard (10 or 25 ng). Samples were homogenized with an ultrasonic cell
disrupter (Model 185, Branson, Danbury, CT, U.S.A.) and centrifuged for 15 min at 4°C in a
microcentrifuge (Model 5412, Brinkmann, Westbury, NY, U.S.A.). A 100—200-μl aliquot
of either the standards or tissue sample supernatants was injected into the chromatograph.
The homogenate pellet was assayed for protein content with the Folin reagent [38] using
bovine serum albumin as a standard.
RESULTS AND DISCUSSION
Effects of methanol, heptanesulfonate, and pH on compound retention
Functional group selectivity was optimized by alterations in the nature and relative
concentrations of the mobile phase components. The relative retention (capacity factor, k′)
of dopamine, DOPAC, HVA, 5-HT, N-methyl-5-HT, 5-HTP and 5-HIAA was found to be a
function of the methanol and heptanesulfonate concentrations, as well as of the pH of the
mobile phase. Decreasing the aqueous characteristics of the mobile phase by increasing the
methanol concentration produced a concentration-dependent decrease in k′ for all
compounds (Fig. 1).
Ion-pair chromatography has been demonstrated to be effective in minimizing the peak
tailing attributed to secondary interactions between polar ionogenic compounds and
*All references indicate the measured pH (“apparent pH”) of the aqueous methanol mixture referred to an aqueous standard buffer
solution.
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unreacted silanol groups on the silica surface and, more importantly, in controlling the
relative retention of such compounds [39—42]. The addition of heptanesulfonate to the
mobile phase produced a concentration-dependent increase in the retention of the protonated
amines, i.e. dopamine, 5-HT and N-methyl-5-HT (Fig. 2). Pentanesulfonate, a less
hydrophobic ion-pair reagent, did not facilitate the chromatographic separation of dopamine,
DOPAC, HVA, 5-HTP, 5-HT, N-methyl-5-HT and 5-HIAA as completely as was possible
using heptanesulfonate.
The observed influence of mobile phase pH on the relative retention of dopamine, DOPAC,
HVA, 5-HTP, 5-HT, N-methyl-5-HT and 5-HIAA is in good agreement with predictions
based on the degree of ionization at a given pH (Fig. 3). As the mobile phase pH increases
relative to the pKa values of DOPAC, HVA and 5-HIAA, they are deprotonated to a greater
extent, resulting in a decrease in their capacity factors (Fig. 3). Conversely, the calculated
capacity factors for the amines (dopamine, 5-HT and N-methyl-5-HT) are relatively
unaffected by the pH range (3—6) examined in the present study since their pKa values
exceed the highest mobile phase pH tested. The capacity factors for the amino acid 5-HTP
exhibit a concave downward relationship with increasing mobile phase pH. This is probably
due to initial deprotonation of the carboxyl group to form the more polar zwitterion followed
by deprotonation of the amino group to yield the amino carboxylate anion.
Internal standardization
The use of internal standards in quantitative analytical procedures is generally considered to
be superior to direct calibration. The addition of N-methyl-5-HT to standards and tissue
samples effectively controlled for variable volumes injected and within-run variations in
column or detector electrode performance. The ratio of the detector response to varied
amounts (0.1—50 ng) of dopamine, DOPAC, HVA, 5-HTP, 5-HT and 5-HIAA relative to a
constant amount of N-methyl-5-HT (10 ng) was a linear function of concentration.
Correlation coefficients for each compound were generally greater than 0.99. 5-Hydroxy-2-
indolecarboxylic acid (Aldrich) elutes after HVA and can be used in place of, or in addition
to, N-methyl-5-HT as an internal standard. Although this compound simplifies establishing
optimal mobile phase parameters for a given column, it increases the total chromatography
time, thereby decreasing sample throughput.
Tissue protein precipitation
The relative effectiveness of the mobile phase in precipitating proteins from tissue
homogenates was also determined. The whole brain from a rat was minced and duplicate
groups of 10, 50 or 100 mg samples were collected. One group was homogenized in 400 μl
of the mobile phase and the other homogenized in 400 μl of 0.1 M perchloric acid.
Following centrifugation and removal of the supernatants, the protein content of the pellet
was determined (Table I). It is apparent from these data that the mobile phase is at least as
effective as 0.1 M perchloric acid in precipitating tissue protein.
Chromatographic interference
The utility of any analytical method is limited by the extent to which endogenous or
exogenous substances interfere with the separation and detection of the compounds of
interest. In this assay, interference will occur only when such substances coelute with one or
more of the compounds of interest and are significantly oxidized at the detector electrode
potential used. A series of catechol and indole derivatives were examined to determine if
either or both of these criteria were applicable. Epinephrine (EPI), norepinephrine (NE) and
DOPA had significant electrochemical activity within the range of detector potentials
examined (0.55—0.75 V). However, these polar compounds elute in the solvent front and
thus would not interfere. Conversely, tyramine and tryptophan coelute with 5-HTP and N-
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methyl-5-HT, respectively, but produce little or no detector response at detector potentials
less than 0.9 V (tryptophan) or 0.8 V (tyramine). The 3-O-methylated metabolites of NE and
EPI, normetanephrine and metanephrine, respectively, eluted immediately prior to and
following dopamine and were electrochemically inactive at detector potentials less than 0.6
V. The deaminated metabolites of NE, 3-methoxy-4-hydroxymandelic acid (VMA) and 3-
methoxy-4-hydroxyphenylglycol (MHPG), elute in the solvent front and prior to 5-HTP,
respectively. The 3-O-methylated metabolite of dopamine, 3-methoxytyramine (3-MT),
eluted between and was incompletely resolved from DOPAC and 5-HT. In agreement with
Shoup and Kissinger [43] no detector response was obtained for 3-MT at detector potentials
less than 0.6 V.
Of these potentially interfering compounds, only 3-MT is a particular source of concern
when assaying dopaminergic systems. Although it interfered slightly with the quantification
of DOPAC and 5-HT, the 3-MT content of the rat brain is relatively small, and does not
compromise the overall accuracy of the assay. Moreover, interference attributed to 3-MT
may be eliminated by sacrificing the rats by head focused microwave irradiation, or by
decreasing the detector electrode potential to 0.6 V. Either course effectively eliminates this
problem, although the latter method results in a concomitant decrease in the electrochemical
activity of HVA.
Sensitivity and within-run reproducibility
Detection limits (in terms of compound injected from an aqueous solution) ranged from 20
—60 pg for dopamine, DOPAC, 5-HTP, 5-HT, N-methyl-5-HT and 5-HIAA and 50—150
pg for HVA, depending on column condition. The within-run precision of the assay was
determined by processing and assaying ten 50-μl aliquots of a sample obtained by
homogenizing a single rat striatum in 500μl of mobile phase containing 250 ng of N-
methyl-5-HT. The estimated coefficients of variation ranged from 6.3% (5-HIAA) to 3.1%
(dopamine).
Effects of volume of sample injected
It is generally accepted that as the volume injected into the HPLC system increases, peak
broadening may occur, resulting in a deterioration of the separation of adjacent
chromatographic peaks. This assumption has limited the number of liquid—liquid or liquid
—solid sample purification techniques which can be used in conjunction with HPLC, as
their use compromises the overall sensitivity by generating dilute solutions from which a
finite volume can be injected. The effect of injection volume on peak symmetry and
resolution was examined by injecting solutions containing 50 ng of dopamine, DOPAC,
HVA, 5-HTP, 5-HT, N-methyl-5-HT and 5-HIAA in varying volumes (20—200 μl). The
peak to peak resolution (Rs) was calculated according to Brown and Krstulovic [44]:
where V and W are the retention volume and base peak width, respectively, for compounds 1
and 2. No significant differences in the resolution of adjacent peaks (Rs ≥ 1.35 in all cases)
were noted with increasing injection volume.
Quantitative determinations
The present method permits the simultaneous determinatin of dopamine, 5-HT, their
deaminated metabolites, as well as 5-HTP (the immediate precursor of 5-HT), from samples
of small brain regions. Representative chromatograms of standards and of samples of rat
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striatum or olfactory tubercle are shown in Fig. 4. The effects of pargyline and RO 4-4602
on the concentrations of these compounds in the striatum, olfactory tubercle and nucleus
accumbens were determined to demonstrate the utility of the present method (Table II). The
tissue concentrations of dopamine, 5-HT and DOPAC are in agreement with those
previously reported [45—47]. The inhibition of monoamine oxidase activity by pargyline
increased the concentrations of dopamine and 5-HT, and decreased the concentrations of
DOPAC, HVA and 5-HIAA, in all brain regions examined. The inhibition of aromatic
amino acid decarboxylase activity by RO 4-4602 increased the 5-HTP concentrations in all
three brain regions to detectable concentrations. The concentrations of dopamine and 5-HT
in the striatum and olfactory tubercle, but not the nucleus accumbens, were significantly
decreased following RO 4-4602 treatment.
Considerations during daily use
It should be noted that differences in the chromatographic performance of commercially
available C18 reversed-phase columns supplied by different manufacturers, or changes in
performance that occur with continuous use of a given column, necessitate the periodic
reoptimization of mobile phase parameters (heptanesulfonate and methanol concentrations,
and pH). However, due to the weak surface energies of the bonded hydrocarbonaceous
phase, a rapid re-equilibration with the column packing is possible when altering mobile
phases [48]. Therefore, optimization of column performance, using the data in Figs. 1—3,
can generally be accomplished in a few hours. In our experience, for columns supplied by
different manufacturers, the necessary mobile phase alterations usually represent a change of
less than 10% in any given parameter compared to values established with prior columns.
In summary, there are several salient features of the present method. The absolute and
relative recovery of the compounds of interest was essentially complete. Furthermore, the
ease of sample preparation permits the assay of 35—40 tissue samples plus a standard curve
in one working day. The versatility of this method is demonstrated by the simultaneous
determination of dopamine, DOPAC, HVA, 5-HTP, 5-HT, 5-HIAA and N-methyl-5-HT in a
single sample. Obviously, use of the assay in whole or part can be tailored to the analytical
demands of a particular experimental design.
Acknowledgments
This work was supported in part by PHS grants Nos. ES-01104, HD-10570, AA-02334 and center grants HD-03110
and MH-33127. C.D.K. holds a postdoctoral National Research Service award (MH-07926), and R.B.M. is an
NIEHS Young Investigator Awardee (ES-02087). The authors thank Ken Ellington for valuable assistance with the
chromatography and Faygele ben Miriam for assistance in the preparation of this manuscript.
References
1. Fibiger HC, Miller JJ. Neuroscience 1977;2:975.
2. Kuczenski R. Brain Res 1979;164:217. [PubMed: 154937]
3. Breese GR, Cooper BR, Mueller RA. Brit J Pharmacol 1974;52:307. [PubMed: 4155993]
4. Carlsson A, Davis JN, Kehr W, Kindqvist M, Atack CV. Naunyn-Schmiedeberg’s Arch Pharmakol
Exp Pathol 1972;275:153.
5. Brodie BB, Costa E, Blabac A, Neff NH, Smookler HH. J Pharmacol Exp Ther 1966;154:493.
[PubMed: 5928249]
6. Roth RH, Murrin LC, Walter JR. Eur J Pharmacol 1976;36:163. [PubMed: 177297]
7. Karoum F, Neff NH, Wyatt RJ. Eur J Pharmacol 1977;44:311. [PubMed: 891608]
8. Wiesel FA, Fri CG, Sedvall G. Eur J Pharmacol 1973;23:104. [PubMed: 4733765]
9. Wilk S, Watson E, Travis B. Eur J Pharmacol 1975;30:238. [PubMed: 1126361]
10. Meek JL, Lofstrandh S. Eur J Pharmacol 1976;37:377. [PubMed: 1085253]
KILTS et al. Page 6













11. Tozer TN, Neff NH, Brodie BB. J Pharmacol Exp Ther 1966;153:177.
12. Neckers LM, Meek JL. Life Sci 1976;19:1579. [PubMed: 994702]
13. Reinhard JF Jr, Wurtman R. Life Sci 1977;21:1741. [PubMed: 604702]
14. Neff NH, Tozer TN, Brodie BB. J Pharmacol Exp Ther 1967;158:214. [PubMed: 6065144]
15. Wiesel FA, Fri CG, Sedvall G. J Neural Transm 1974;35:319. [PubMed: 4436671]
16. Watson E, Travis B, Wilk S. Life Sci 1974;15:2167.
17. Gelpi E, Peralta E, Segura J. J Chromatogr Sci 1974;12:701. [PubMed: 4418357]
18. Cattabeni F, Koslow SH, Costa E. Science 1972;178:166. [PubMed: 5076906]
19. Swahn CG, Sandgarde B, Wiesel FA, Sedvall G. Psychopharmacology 1976;48:147. [PubMed:
826926]
20. Beck O, Wiesel FA, Sedvall G. J Chromatogr 1977;134:407. [PubMed: 140179]
21. Artigas F, Gelpi E. Anal Biochem 1979;92:233. [PubMed: 426283]
22. Meek JL, Neckers LM. Brain Res 1975;91:336. [PubMed: 1164684]
23. Meek JL. Anal Chem 1976;48:375. [PubMed: 1082277]
24. Beck O, Palmskog G, Hultman E. Clin Chim Acta 1977;79:149. [PubMed: 890947]
25. Davis TP, Gehrke CW, Gehrke CW Jr, Cunningham TD, Kuo KC, Gerhardt KO, Johnson HD,
Williams CH. Clin Chem 1978;24:1317. [PubMed: 679455]
26. Keller R, Oke A, Mefford I, Adams RN. Life Sci 1976;19:995. [PubMed: 994718]
27. Scratchley GA, Masoud AN, Stohs SJ, Wingard DW. J Chromatogr 1979;169:313. [PubMed:
536421]
28. Hefti F. Life Sci 1979;25:775. [PubMed: 491856]
29. Wightman RM, Plotsky PM, Strope E, Delcore R Jr, Adams RN. Brain Res 1977;131:345.
[PubMed: 890461]
30. Felice LJ, Kissinger PT. Anal Chem 1976;48:794. [PubMed: 1267156]
31. Felice LJ, Bruntlett CS, Kissinger PT. J Chromatogr 1977;143:407. [PubMed: 885980]
32. Sasa S, Blank CL. Anal Chem 1977;49:354. [PubMed: 842846]
33. Ponzio F, Jonsson G. J Neurochem 1979;32:129. [PubMed: 759564]
34. Warsh JJ, Chiu A, Godse DD, Coscina DV. Brain Res Bull 1979;4:567. [PubMed: 487209]
35. Gamier JP, Bousquet B, Dreux C. J Liquid Chromatogr 1979;2:539.
36. Koch DD, Kissinger PT. J Chromatogr 1979;164:441.
37. Mefford IN, Barchas JD. J Chromatogr 1980;181:187. [PubMed: 6154716]
38. Lowry DH, Rosebrough NJ, Farr AL, Randall RJ. J Biol Chem 1951;193:265. [PubMed:
14907713]
39. Wittmer DP, Nuessle NO, Haney WG. Anal Chem 1975;47:1422. [PubMed: 1147263]
40. Knox JH, Jurand J. J Chromatogr 1976;125:89. [PubMed: 977684]
41. Kraak JC, Jonker KM, Huber JFK. J Chromatogr 1977;142:671. [PubMed: 914941]
42. van de Venne JLM, Hendrikx JLHM, Deelder RS. J Chromatogr 1978;167:1.
43. Shoup RE, Kissinger PT. Clin Chem 1977;23:1268. [PubMed: 872373]
44. Brown PR, Krstulovic AM. Anal Biochem 1979;99:1. [PubMed: 43683]
45. Brownstein M, Saavedra JM, Palkovits M. Brain Res 1974;79:431. [PubMed: 4214258]
46. Saavedra JM. Fed Proc, Fed Amer Soc Exp Biol 1977;36:2134. [PubMed: 872947]
47. Fekete MIK, Herman JP, Kanyicska B, Palkovits M. J Neural Transm 1979;45:207. [PubMed:
479873]
48. Karger BL, Giese RW. Anal Chem 1978;50:1048A.
KILTS et al. Page 7














Effect of methanol concentration of the mobile phase on the retention of DA, 5-HTP,
DOPAC, 5-HT, 5-HIAA, N-methyl-5-HT and HVA. Mobile phase: citrate—Na2HPO4, 0.75
mM heptanesulfonate, pH 3.9. The capacity factor, k′, was calculated by k′ = (tR − tvv)
tvvwhere tR is the retention time of the compound of interest and tvv the retention time of an
unretarded component (representing the time to displace one column void volume).
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Effect of heptanesulfonate concentration of the mobile phase on the retention of DA, 5-HTP,
DOPAC, 5-HT, N-methyl-5-HT, 5-HIAA and HVA. Mobile phase: citrate— Na2HPO4,
14% methanol, pH 3.9. See legend to Fig. 1 for derivation of k′.
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Effect of pH of the mobile phase on the retention of DA, 5-HTP, DOPAC, 5-HT, N-
methyl-5-HT, 5-HIAA and HVA. Mobile phase: citrate—Na2HPO4, 0.75 mM
heptanesulfonate, 14% methanol. Orthophosphoric acid (85%) or 1 N sodium hydroxide
were used to titrate the mobile phase to the desired pH. See legend to Fig. 1 for derivation of
k′.
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Chromatograms of 50 μl of a mixture containing 1 ng/μl of the reference and internal
standards and of supernatants from rat striatum or olfactory tubercles. Peaks: 1 = DA; 2 = 5-
HTP; 3 = DOPAC; 4 = 5-HT; 5 = N-methyl-5-HT; 6 = 5-HIAA; 7 = HVA. Detector
sensitivities (using a 1-V recorder) were: 50 nA/V for standards; A = change of sensitivity
from 200 to 50 nA/V; B = change of sensitivity from 50 to 20 nA/V. See text for
chromatography conditions.
KILTS et al. Page 11

























KILTS et al. Page 12
TABLE I
PROTEIN CONTENT (mg) OF BRAIN MINCES HOMOGENIZED IN MOBILE PHASE* OR 0.1 M
PERCHLORIC ACID
Approximate tissue weight (mg)
Solvent
Mobile phase 0.1 M perchloric acid
10 0.87 ± 0.09 1.05 ± 0.15
50 5.4± 0.4 4.4 ± 0.2
100 11.5 ±0.6 9.8 ± 0.4
*
See text for mobile phase composition.
Values represent mean ± S.E.M. for 3 separate determinations.
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